Urachal carcinoma: A novel staging system utilizing the National Cancer Database

Authors: Limonnik, Vladimir, Samiei, Arash, Abel, Stephen, Wegner, Rodney E., Vemana, Goutham, Mao, Shifeng S.

Source: Cancer medicine. 12(3):2752-2760

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100175787763.0x000001&indx=1&recIds=ETOCvdc_100175787763.0x000001

Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial.

Authors: Marshall, Catherine H., Teply, Benjamin A., Lu, Jiayun, Oliveira, Lia, Wang, Hao, Mao, Shifeng S., Kelly, W. Kevin, Paller, Channing J., Markowski, Mark C., Denmeade, Samuel R., King, Serina, Sullivan, Rana, Davicioni, Elai, Proudfoot, James A., Eisenberger, Mario A., Carducci, Michael A., Lotan, Tamara L., Antonarakis, Emmanuel S.

Source: JAMA Oncology; Oct2024, Vol. 10 Issue 10, p1400-1408, 9p

PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.

Authors: Paller, Channing Judith, Lorentz, Justin, DeMarco, Tiffani, Stadler, Walter Michael, Armstrong, Andrew J., Taplin, Mary-Ellen, Hussain, Maha H. A., Pili, Roberto, Mao, Shifeng S., Elrod, Jo Ann, Sokolova, Alexandra, Heath, Elisabeth I., McKay, Rana R., Vinson, Jake, Green, Rebecca, Tran, Christina, Macario, Natalie, Cook, Audrey, Chiang, Jenny, Cheng, Heather H.

Source: Journal of clinical oncology. 40(6 suppl):TPS191-TPS191

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100152983647.0x000001&indx=1&recIds=ETOCvdc_100152983647.0x000001

Systematic Review and Meta-Analysis of Cisplatin Based Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer

Authors: Benkhadra, Raed, Nayfeh, Tarek, Patibandla, Sai Krishna, Peterson, Chelsea, Prokop, Larry, Alhalabi, Omar, Murad, M. Hassan, Mao, Shifeng S.

Source: Bladder Cancer; March 2022, Vol. 8 Issue: 1 p5-17, 13p

Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy.

Authors: Marshall, Catherine Handy, Teply, Benjamin A., Lim, Su Jin, Wang, Hao, Mao, Shifeng S., Kelly, William Kevin, Paller, Channing Judith, Markowski, Mark Christopher, Denmeade, Samuel R., Carducci, Michael Anthony, Eisenberger, Mario A., King, Serina, Sullivan, Rana, Lotan, Tamara L., Antonarakis, Emmanuel S.

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p5087-5087, 1p

Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC).

Authors: Beckermann, Katy, Campbell, Matthew T, Haas, Naomi B., Ornstein, Moshe Chaim, Gao, Xin, Mao, Shifeng S., Hammers, Hans J., George, Saby, Nelson, Ariel Ann, Gourdin, Theodore Stewart, Keshava-Prasad, Holavanahalli, Hussain, Arif, Hoimes, Christopher J., Yan, Hongxia, Esquibel, Vanessa, McIntyre, Gail, Geller, Robert B., Voss, Martin H, Rini, Brian I., Shah, Neil J.

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p4534-4534, 1p

Learned lessons from a US-wide outreach program to broaden enrollment to the PROMISE Registry, a prostate cancer genetic registry.

Authors: Paller, Channing Judith, Lorentz, Justin, Appleman, Leonard Joseph, Armstrong, Andrew J., Barata, Pedro C., Dreicer, Robert, Elrod, Jo Ann, Fleming, Mark T., George, Christopher M., Heath, Elisabeth I., Hussain, Maha H. A., Mao, Shifeng S., McKay, Rana R., Morgans, Alicia K., Orton, Matthew, Pili, Roberto, Saraiya, Biren, Sokolova, Alexandra, Stadler, Walter Michael, Cheng, Heather H.

Source: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p10628-10628, 1p

PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.

Authors: Paller, Channing Judith, Lorentz, Justin, Appleman, Leonard Joseph, Armstrong, Andrew J., Barata, Pedro C., Dreicer, Robert, Elrod, Jo Ann, Fleming, Mark T., George, Christopher M., Heath, Elisabeth I., Hussain, Maha H. A., Mao, Shifeng S., McKay, Rana R., Morgans, Alicia K., Orton, Matthew, Pili, Roberto, Saraiya, Biren, Sokolova, Alexandra, Stadler, Walter Michael, Cheng, Heather H.

Source: Journal of Clinical Oncology; 2/21/2023 Supplement, Vol. 41, pTPS274-TPS274, 1p

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC).

Authors: Shah, Neil J., Campbell, Matthew T, Mao, Shifeng S., Ornstein, Moshe Chaim, Haas, Naomi B., Gao, Xin, Hammers, Hans J., Keshava-Prasad, Holavanahalli, Yan, Hongxia, Esquibel, Vanessa, Geller, Robert B., Beckermann, Katy

Source: Journal of Clinical Oncology; 2/21/2023 Supplement, Vol. 41, p666-666, 1p